UPDATE 1-Boston Scientific posts weaker quarterly results
* Fourth-quarter net income falls to 4 cents a share from 7 cents
Excluding items, earnings of 11 cents a share match Wall Street view
* Sales slip to $1.82 billion from $1.85 billion
* Full-year sales seen at $7.05 billion to $7.35 billion
Jan 29 (Reuters) - Medical device maker Boston Scientific Corp posted weaker quarterly earnings on Tuesday as sales slipped and expenses rose.
Fourth-quarter net earnings were $60 million, or 4 cents per share, down from $107 million, or 7 cents per share, a year earlier.
Excluding special items, earnings were 11 cents per share, matching the average estimate on Wall Street, according to Thomson Reuters I/B/E/S.
Revenue dipped to $1.82 billion from $1.85 billion as sales slipped in the interventional cardiology business, which sells heart stents, and in the cardiac rhythm management business, which sells pacemakers and implantable heart defibrillators. Those two businesses make up more than half of Boston Scientific's total revenue.
Sales rose in the company's other smaller businesses, including urology and women's heath, endoscopy and neuromodulation.
The company forecast first-quarter earnings of 4 cents to 7 per share. It expects adjusted earnings, excluding charges for restructuring, acquisitions and amortization, to be 14 cents to 17 cents per share, with sales of $1.74 billion to $1.82 billion.
For the full year, Boston Scientific estimated earnings at 29 cents to 37 cents per share. It said it expected adjusted earnings of between 64 cents and 70 cents per share on sales of $7.05 billion to $7.35 billion.